Prolonged duration of response in lenvatinib responders with thyroid cancer

por Gianoukakis, Andrew G, Dutcus, Corina E, Batty, Nicolas, Guo, Matthew, Baig, Mahadi
Publicado 2018

Exposure–response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer

por Hayato, Seiichi, Shumaker, Robert, Ferry, Jim, Binder, Terri, Dutcus, Corina E., Hussein, Ziad
Publicado 2018

An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Patients with Advanced Solid Tumors

por Shumaker, Robert, Ren, Min, Aluri, Jagadeesh, Dutcus, Corina E., Rance, Christian, He, Cixin
Publicado 2020

Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate Versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer

por Twelves, Chris, Awada, Ahmad, Cortes, Javier, Yelle, Louise, Velikova, Galina, Olivo, Martin S., Song, James, Dutcus, Corina E., Kaufman, Peter A.
Publicado 2016

Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study

por Tibes, Raoul, Borad, Mitesh J., Dutcus, Corina E., Reyderman, Larisa, Feit, Kevie, Eisen, Andrew, Verbel, David A., Von Hoff, Daniel D.
Publicado 2018

Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracyclin...

por Kaufman, Peter A., Awada, Ahmad, Twelves, Chris, Yelle, Louise, Perez, Edith A., Velikova, Galina, Olivo, Martin S., He, Yi, Dutcus, Corina E., Cortes, Javier
Publicado 2015

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

por Taylor, Matthew H., Lee, Chung-Han, Makker, Vicky, Rasco, Drew, Dutcus, Corina E., Wu, Jane, Stepan, Daniel E., Shumaker, Robert C., Motzer, Robert J.
Publicado 2020

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

por Kiyota, Naomi, Robinson, Bruce, Shah, Manisha, Hoff, Ana O., Taylor, Matthew H., Li, Di, Dutcus, Corina E., Lee, Eun Kyung, Kim, Sung-Bae, Tahara, Makoto
Publicado 2017

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes

por Haddad, Robert I., Schlumberger, Martin, Wirth, Lori J., Sherman, Eric J., Shah, Manisha H., Robinson, Bruce, Dutcus, Corina E., Teng, Angela, Gianoukakis, Andrew G., Sherman, Steven I.
Publicado 2017

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer

por Robinson, Bruce, Schlumberger, Martin, Wirth, Lori J., Dutcus, Corina E., Song, James, Taylor, Matthew H., Kim, Sung-Bae, Krzyzanowska, Monika K., Capdevila, Jaume, Sherman, Steven I., Tahara, Makoto
Publicado 2016

Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma

por Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.
Publicado 2019

Correction: Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular...

por Evans, Thomas R. Jeffry, Kudo, Masatoshi, Finn, Richard S., Han, Kwang-Hyub, Cheng, Ann-Lii, Ikeda, Masafumi, Kraljevic, Silvija, Ren, Min, Dutcus, Corina E., Piscaglia, Fabio, Sung, Max W.
Publicado 2019

Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma

por Lee, Chung-Han, Motzer, Robert J., Glen, Hilary, Michaelson, M. D., Larkin, James, Minoshima, Yukinori, Kanekiyo, Michio, Ikezawa, Hiroki, Sachdev, Pallavi, Dutcus, Corina E., Funahashi, Yasuhiro, Voss, Martin H.
Publicado 2020

Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib

por Taylor, Matthew H., Takahashi, Shunji, Capdevila, Jaume, Tahara, Makoto, Leboulleux, Sophie, Kiyota, Naomi, Dutcus, Corina E., Xie, Ran, Robinson, Bruce, Sherman, Steven, Habra, Mouhammed Amir, Elisei, Rossella, Wirth, Lori J.
Publicado 2021

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

por Makker, Vicky, Aghajanian, Carol, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., Messing, Mark, Dutta, Lea, Dutcus, Corina E., Huang, Jie, Schmidt, Emmett V., Orlowski, Robert, Taylor, Matthew H.
Publicado 2023

Lenvatinib for Anaplastic Thyroid Cancer

por Tahara, Makoto, Kiyota, Naomi, Yamazaki, Tomoko, Chayahara, Naoko, Nakano, Kenji, Inagaki, Lina, Toda, Kazuhisa, Enokida, Tomohiro, Minami, Hironobu, Imamura, Yoshinori, Sasaki, Tatsuya, Suzuki, Takuya, Fujino, Katsuki, Dutcus, Corina E., Takahashi, Shunji
Publicado 2017

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies

por Motzer, Robert J., Taylor, Matthew H., Evans, Thomas R. Jeffry, Okusaka, Takuji, Glen, Hilary, Lubiniecki, Gregory M., Dutcus, Corina, Smith, Alan D., Okpara, Chinyere E., Hussein, Ziad, Hayato, Seiichi, Tamai, Toshiyuki, Makker, Vicky
Publicado 2022

A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer

por Brose, Marcia S, Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G M, Gianoukakis, Andrew G, Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K, Leboulleux, Sophie, Binder, Terri A, Dutcus, Corina, Xie, Ran, Taylor, Matthew H
Publicado 2021

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

por Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard, Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max, Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Mody, Kalgi, Dutcus, Corina, Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, Kumada, Hiromitsu
Publicado 2021

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

por Makker, Vicky, Taylor, Matthew H., Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., DiSimone, Christopher, Messing, Mark, Stepan, Daniel E., Dutcus, Corina E., Wu, Jane, Schmidt, Emmett V., Orlowski, Robert, Sachdev, Pallavi, Shumaker, Robert, Casado Herraez, Antonio
Publicado 2020